Please visit one of our specialized providers for an assessment
For weight management, GLP-1 use generally applies to people who meet one of the following criteria: A BMI of at least 30 , or A BMI of at least 27, along with a weight-related condition like high blood pressure or high cholesterol Who shouldnt take tirzepatide or Wegovy
Stay committed to your treatment plan for best results
Semaglutide/Cyanocobalamin is an injectable glucagon-like peptide-1 (GLP-1) agonist thats administered once weekly
Disclosure of interest: nothing to disclose Scientific Communications: risk factors 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS O - ESOC25-2033 CLINICAL CHARACTERISTICS ASSOCIATED WITH NOT USING ORAL ANTICOAGULANTS AT THE TIME OF FIRST ISCHEMIC STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: A NATIONWIDE STUDY Marko Vilpponen 1 , Jukka Putaala 2 , Aapo Aro 3 , Mika Lehto 4 , Olli Halminen 5 , Paula Tiili 6 , Miika Linna 5 , Alex Luojus 7 , Konsta Teppo 8 , Pirjo Mustonen 8 , Jari Haukka 9 , Juha Hartikainen 10 , Juhani Airaksinen 8 1 University of Helsinki, Helsinki, Finland, 2 Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland, Helsinki, Finland, 3 Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland, Helsinki, Finland, 4 Department of Internal Medicine, Jorvi Hospital and Helsinki University Hospital, Espoo, Finland and University of Helsinki, Finland, Espoo, Helsinki, Finland, 5 Department of Industrial Engineering and Management, Aalto University, Espoo, Finland, Helsinki, Finland, 6 Primary Health Care Unit, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland, 7 University of Helsinki, Finland;, Helsinki, Finland, 8 Heart Center, Turku University Hospital and University of Turku, Finland, Turku, Finland, 9 Department of Public Health, University of Helsinki, Finland, Helsinki, Finland, 10 Heart Center, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland, Kuopio, Finland Background and Aims: This study identifies the characteristics of AF (atrial fibrillation) patients at the time of their first IS (ischemic stroke) episode who were not on OAC (oral anticoagulation) therapy
Whether this distinct property of saxagliptin could interact with pathways of bone metabolism and bone turnover, thus having a relatively negative impact on bone mass or strength, needs to be elucidated
